10/616,579

Connecting via Winsock to STN

Welcome to STN International! Enter x:

Welcome to STN International! Enter x:

Welcome to STN International! Enter x:

Sorry. Your logon could not be completed because
no recognized response was received from the gateway system.
Please check the gateway "Prompt Characters strings".

Welcome to STN International! Enter x:x

LOGINID:ssspta1203mxm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:41:04 ON 09 MAR 2005

=> file reg

=>
Uploading C:\Program Files\Stnexp\Queries\10616579.str



chain nodes :
11 12 13 14 15 18 19
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
2-11 11-12 11-18 12-13 12-14 14-15 14-19

ring bonds :
1-2 1-6 1-10 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10
exact/norm bonds :
2-11 11-12 11-18 12-13 12-14 14-15 14-19
normalized bonds :
1-2 1-6 1-10 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10
isolated ring systems :
containing 1 :

G1:O,S

G2:H,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 18:CLASS 19:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S
G2 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
L3 325 SEA SSS FUL L1

=> file ca

=> s l3

10/616,579

L4 15 L3

=> d ibib abs fhitstr 1-15

L4 ANSWER 1 OF 15 CA COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 141:174087 CA
TITLE: Preparation of fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1)
INVENTOR(S): Lee, Chih-Hung; Bayburt, Erol K.; Didomenico, Stanley; Drizin, Irene; Gomtsyan, Arthur R.; Koenig, John R.; Perner, Richard J.; Schmidt, Robert G.; Turner, Sean C.; White, Tammie K.; Zheng, Guo Zhu
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 93 pp., Cont.-in-part of U.S. Ser. No. 364,210.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004157849	A1	20040812	US 2003-634678	20030805
US 2003158198	A1	20030821	US 2003-364210	20030211
WO 2005016890	A1	20050224	WO 2004-US25109	20040804

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-364210 A2 20030211
US 2002-358220P P 20020220
US 2003-634678 A 20030805
OTHER SOURCE(S): MARPAT 141:174087
GI


I


II

AB Compds. of formula I [X1-X5 = (substituted) N, (substituted) CH; Z1 = O, NH, S; Z2 = bond, NH, O; L = alkylene, cycloalkylene, piperazinediyl, etc.; R5-R9 = H, alkyl, alkenyl, alkoxy, carboxy, cycloalkyl, formyl,

L4 ANSWER 1 OF 15 CA COPYRIGHT 2005 ACS on STN (Continued)
mercapto, etc.; R10 = H, aryl, cycloalkyl, heterocyclyl] are prepd. as vanilloid receptor subtype 1 (VR1) antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity. Thus, II was prepd. from 5-aminoisoquinoline and 2-(3-fluorophenyl)ethylamine. The prepd. compds. were found to be antagonists of VR1 with IC50 of 0.1 nM to 1000 nM.
IT **581809-65-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused azabicyclic compds. as vanilloid receptor 1 inhibitors)
RN 581809-65-6 CA
CN Urea, N-[2-(3-fluorophenyl)ethyl]-N'-5-isoquinolinyl- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 15 CA COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 141:157010 CA
TITLE: N-Isoquinolin-5-yl-N'-aralkyl-urea and -amide antagonists of human vanilloid receptor 1
AUTHOR(S): Jetter, Michele C.; Youngman, Mark A.; McNally, James J.; Zhang, Sui-Po; Dubin, Adrienne E.; Nasser, Nadia; Dax, Scott L.
CORPORATE SOURCE: Johnson & Johnson Pharmaceutical Research and Development, Spring House, PA, 19477, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(12), 3053-3056
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:157010
AB Starting from a low micromolar agonist lead identified by high-throughput screening, series of N-isoquinolin-5-yl-N'-aralkyl ureas and analogous amides were developed as potent antagonists of human vanilloid receptor 1 (VR1). The synthesis and structure-activity relationships (SAR) of the series are described.
IT **581809-67-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of n-isoquinolin-5-yl-N'-aralkyl-urea and -amide including their structure-activity relationships as antagonists of human vanilloid receptor 1)
RN 581809-67-8 CA
CN Urea, N-5-isoquinolinyl-N'-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 15 CA COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 141:46759 CA
TITLE: Design and synthesis of Rho kinase inhibitors (I)
AUTHOR(S): Takami, Atsuya; Iwakubo, Masayuki; Okada, Yuji; Kawata, Takehisa; Odai, Hideharu; Takahashi, Nobuaki; Shindo, Kazutoshi; Kimura, Kaname; Tagami, Yoshimichi; Miyake, Mika; Fukushima, Kayoko; Inagaki, Masaki; Amano, Mutsuki; Kaibuchi, Kozo; Iijima, Hiroshi
CORPORATE SOURCE: Pharmaceutical Research Laboratories, Kirin Brewery Co. Ltd., Gunma, Takasaki-shi, 370-1295, Japan
SOURCE: Bioorganic & Medicinal Chemistry (2004), 12(9), 2115-2137
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:46759
AB Several structurally unrelated scaffolds of the Rho kinase inhibitor were designed using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homol. model of Rho kinase. A docking simulation using the ligand-binding pocket of the Rho kinase model helped to comprehensively understand and to predict the structure-activity relationship of the inhibitors. This understanding was useful for developing new Rho kinase inhibitors of higher potency and selectivity. We identified several potent platforms for developing the Rho kinase inhibitors, namely, pyridine, 1H-indazole, isoquinoline, and phthalimide.
IT **709046-05-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(design and synthesis of Rho kinase inhibitors)
RN 709046-05-9 CA
CN Urea, N-[(2,6-difluorophenyl)methyl]-N'-5-isoquinolinyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 15 CA COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 140:111290 CA
TITLE: Preparation of naphthalenylureas, quinolinylureas, and isoquinolinylureas as modulators of vanilloid VR1 receptor ligands.
INVENTOR(S): Codd, Ellen; Dax, Scott L.; Jetter, Michele; Mcdonnell, Mark; Mcnally, James J.; Youngman, Mark
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 205 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007459	A2	20040122	WO 2003-US21518	20030710
WO 2004007459	A3	20040318		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004157865	A1	20040812	US 2003-616579	20030710
PRIORITY APPLN. INFO.:			US 2002-395728P P	20020712
			US 2002-395951P P	20020715

OTHER SOURCE(S): MARPAT 140:111290
GI



I

AB Title compds. [I; R1, R2 = H, OH, halo, (substituted) alkyl, alkoxy, alkylthio, cycloalkyl, cycloalkoxy, etc.; R3 = H, OH, F, Cl, NO2, amino; L = (substituted) alkylene; R4, R5 = H, alkyl; R6 = (substituted) Ph, naphthyl, heteroaryl, cycloalkyl, heterocyclyl; X = CH, N, NO; Y = C, N; Z = O, S], were prepared as potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain. Thus, (1-chloroisoquinolin-5-yl)carbamic acid Ph ester and 4-trifluoromethylbenzylamine were stirred overnight in DMSO to give 61%

L4 ANSWER 4 OF 15 CA COPYRIGHT 2005 ACS on STN (Continued)
1-(1-chloroisoquinolin-5-yl)-3-(4-trifluoromethylbenzyl)urea. I bound to VR1 receptors with Ki = 0.10-100,000 nM.
IT **581809-67-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of naphthalenylureas, quinolinylureas, and isoquinolinylureas
as modulators of vanilloid VR1 receptor ligands)
RN 581809-67-8 CA
CN Urea, N-5-isoquinolinyl-N'-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 15 CA COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 139:292162 CA
TITLE: Heteroaromatic ureas as vanilloid receptor (VR1) modulators, in particular antagonists, for treating pain and/or inflammation
INVENTOR(S): Brown, Rebecca Elizabeth; Doughty, Victoria Alexandra; Hollingworth, Gregory John; Jones, A. Brian; Lindon, Matthew John; Moyes, Christopher Richard; Rogers, Lauren
PATENT ASSIGNEE(S): Merck Sharp & Dohme Limited, UK
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080578	A1	20031002	WO 2003-GB1302	20030321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2479150	AA	20031002	CA 2003-2479150	20030321
EP 1490340	A1	20041229	EP 2003-710014	20030321
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			GB 2002-6876 A	20020322
			WO 2003-GB1302 W	20030321

OTHER SOURCE(S): MARPAT 139:292162
GI



I

AB Title compds. I (wherein A, B, D, E are each C or N with the proviso that one or more are N; R1, R2 = independently H, halo, alk(enyl/ynyl), haloalkyl, hydroxyalkyl, cycloalkyl, cycloalkylalkyl, NH2 and derivs., CO2H and derivs., (un)substituted alkyl, alkoxy; R3, R4 = independently H, alk(en/yn)yl; R5, R6 = at each occurrence, independently H, alk(enyl/ynyl), alkoxy, acyloxy, carboxy and derivs., CONH2 and derivs., sulfonyl(alkyl/amino), aryl, hetero(aryl/cyclyl), (un)substituted alkyl; or CR5R6 = 3-6 carbocyclic membered ring; R7, R8 = at each occurrence, independently H, alk(en/yn)yl, cycloalkyl, fluoroalkyl; or NR7R8 =

L4 ANSWER 5 OF 15 CA COPYRIGHT 2005 ACS on STN (Continued)
(un)substituted 4-7 heteroaliph. membered ring; X = O, S or =NCN; Y = aryl, heteroaryl, carbocyclyl, fused carbocyclyl group; n = 0, 1, 2, 3; and their pharmaceutically acceptable salts, N-oxides, and prodrugs] were prepd. as vanilloid receptor (VR1) modulators, in particular antagonists, for treating conditions or diseases in which pain and/or inflammation predominates. For example, 1-isoquinolin-5-yl-3-(3-phenylpropyl)urea was prepd. by reacting isoquinoline-5-carboxylic acid with diphenylphosphoryl azide in toluene at reflux for 1 h through a Curtius rearrangement, followed by addn. of 3-phenylpropylamine and reflux for 18 h. I bound to the VR1 receptor with an IC50 < 1 μM, and in the majority of cases, < 200 nM. I are predominantly VR1 antagonists with a few of them VR1 partial antagonists and VR1 partial agonists. Thus, I and their pharmaceutical compns. are useful for treating pain and/or inflammation.
IT **581809-67-8P**, 1-Isoquinolin-5-yl-3-[4-(trifluoromethyl)benzyl]urea
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(VR1 receptor ligand; preparation of heteroarom. ureas as vanilloid receptor
modulators for treating pain and inflammation)
RN 581809-67-8 CA
CN Urea, N-5-isoquinolinyl-N'-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 15 CA COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 139:197383 CA
TITLE: Preparation of fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1)
INVENTOR(S): Lee, Chih-Hung; Bayburt, Erol K.; Didomenico, Stanley; Drizin, Irene; Gomtsyan, Arthur R.; Koenig, John R.; Perner, Richard J.; Schmidt, Robert G.; Turner, Sean C.; White, Tammie K.; Zheng, Guo Zhu
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 79 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003158198	A1	20030821	US 2003-364210	20030211
CA 2476936	AA	20030828	CA 2003-2476936	20030211
WO 2003070247	A1	20030828	WO 2003-US4187	20030211
W: CA, JP, MX				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
EP 1478363	A1	20041124	EP 2003-716014	20030211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004157849	A1	20040812	US 2003-634678	20030805
US 2004209884	A1	20041021	US 2004-842311	20040510

PRIORITY APPLN. INFO.:

US 2002-358220P	P	20020220
US 2002-79324	A	20020220
US 2003-364210	A	20030211
WO 2003-US4187	W	20030211

OTHER SOURCE(S): MARPAT 139:197383
GI


I


II

AB Compds. of formula I [X1-X5 = (substituted) N, (substituted) CH; Z1 = O, NH, S; Z2 = bond, NH, O; L = alkylene, cycloalkylene, piperazinediyl, etc.; R5-R9 = H, alkyl, alkenyl, alkoxy, carboxy, cycloalkyl, formyl, mercapto, etc.; R10 = H, aryl, cycloalkyl, heterocyclyl] are prepared as vanilloid receptor subtype 1 (VR1) antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder

L4 ANSWER 6 OF 15 CA COPYRIGHT 2005 ACS on STN (Continued)
overactivity. Thus, II was prepd. from 5-aminoisoquinoline and 2-(3-fluorophenyl)ethylamine. The prepd. compds. were found to be antagonists of VR1 with IC50 of.1 nM to 1000 nM.
IT **581809-65-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused azabicyclic compds. as vanilloid receptor 1 inhibitors)
RN 581809-65-6 CA
CN Urea, N-[2-(3-fluorophenyl)ethyl]-N'-5-isoquinolinyl- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 15 CA COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 139:197382 CA
TITLE: Preparation of isoquinolines, indoles, and related compounds as antagonists of vanilloid receptor subtype 1 (VR1).
INVENTOR(S): Lee, Chih-Hung; Bayburt, Erol K.; Didomenico, Stanley; Drizin, Irene; Gomtsyan, Arthur R.; Koenig, John R.; Perner, Richard J.; Schmidt, Robert G.; Turner, Sean C.; White, Tammie K.; Zheng, Guo Zhu
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 38 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003158188	A1	20030821	US 2002-79324	20020220
CA 2476936	AA	20030828	CA 2003-2476936	20030211
WO 2003070247	A1	20030828	WO 2003-US4187	20030211
W: CA, JP, MX				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
EP 1478363	A1	20041124	EP 2003-716014	20030211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:

US 2002-79324	A	20020220
US 2003-364210	A	20030211
WO 2003-US4187	W	20030211

OTHER SOURCE(S): MARPAT 139:197382
GI


I

AB Title compds. [I; X1 = N, CR1; X2 = N, CR2; X3 = N, NR3, CR3; X4 = null, N, CR4; X5 = N, CH2; Z1 = O, NH, S; Z2 = NH, O; L = piperazinylene, alkenylene, alkylene, alkynylene, cycloalkylene, (CH2)mO(CH2)n, NHO, NHNH; m, n = 1-6; R1, R3, R5, R6, R7 = H, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, A, ACO, ACOA, AO2, AS, alkynyl, CO2H, AO2H, cyano, cyanoalkyl, cycloalkyl, cycloalkylalkyl, ethylenedioxy, CHO, ACHO, haloalkoxy, haloalkyl, haloalkylthio, halo, OH, HOA, methylenedioxy, SH, ASH, NO2, (CF3)2(HO)C, NRAS02RB, SO2ORA, SO2RB, NZAZB, (NZAZB)A, (NZAZB)CO, (NZAZB)COA, (NZAZB)SO2; ZA, ZB = H, A, ACO, CHO, aryl, aralkyl; R2, R4 = H, alkenyl, AO, alkoxyalkoxy, AOA, AO2C,

L4 ANSWER 7 OF 15 CA COPYRIGHT 2005 ACS on STN (Continued)
AO2CA, A, ACO, ACOA, ACO2, AS, alkynyl, CO2H, carboxyalkyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylalkyl, ethylenedioxy, CHO, ACHO, haloalkoxy, haloalkyl, haloalkylthio, halo, OH, HOA, methylenedioxy, SH, HSA, NO2, (CF3)2(HO)C, NRAS(O)2RB, SO2ORA, SO2RB, NZAZB, (NZAZB)alkyl, (NZAZB)ACO, (NZAZB)CO, (NZAZB)COA, (NZAZB)SO2, (NZAZB)C(:NH), (NZAZB)C(:NCN)NH, (NZAZB)C(:NH)NH; RA = H, A; RB = A, aryl, aralkyl; R8 = null, H, A; R9 = H, aryl, heterocycle; A = alkyl; dotted line = optional double bond], were prepd. for treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity (no data). Thus, 2,2,2-trichloro-N-isoquinolin-5-ylacetamide, (prepn. given) DBU, and 2-(3-fluorophenyl)ethylamine in acetonitrile were refluxed for 10 h to give 65% N-[2-(3-fluorophenyl)ethyl]-N'-isoquinolin-5-ylurea.
IT **581810-09-5P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(claimed compound; preparation of isoquinolines, indoles, and related compds. as antagonists of vanilloid receptor subtype 1)
RN 581810-09-5 CA
CN Urea, N-[(3,5-dimethylphenyl)methyl]-N'-5-isoquinolinyl- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 15 CA COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 139:85361 CA
TITLE: Preparation of ureas as vanilloid receptor (VR1) antagonists
INVENTOR(S): Rami, Harshad Kantilal; Thompson, Hervyn
PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003053945	A2	20030703	WO 2002-GB5812	20021219
WO 2003053945	A3	20040311		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1474403	A2	20041110	EP 2002-788192	20021219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

PRIORITY APPLN. INFO.: GB 2001-30550 A 20011220
WO 2002-GB5812 W 20021219
OTHER SOURCE(S): MARPAT 139:85361
GI


I


II


III

L4 ANSWER 8 OF 15 CA COPYRIGHT 2005 ACS on STN (Continued)

AB The title compds. [I; P = Ph, naphthyl, heterocyclyl; R1 = H, halo, alkyl, etc.; R2 = II; X = a bond, C, O, NR8; R3 = H, halo, alkyl, etc.; R4 = H, alkyl; R8 = H, alkyl, aryl; n = 2-6; p = 0-4; q = 0-3; r = 0-2], useful for treating disorders or diseases in which an antagonist of the vanilloid receptor (VR1) is beneficial, were prepared Thus, reacting 2-(7-fluoro-2,3-dihydrobenzo[1,4]oxazin-4-yl)ethylamine (preparation given) with 2-bromophenyl isocyanate in CH2Cl2 afforded 96% III which had a pKb > 7.0 in test for vanilloid receptor (VR1) antagonist activity.

IT **552866-91-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ureas as vanilloid receptor (VR1) antagonists)

RN 552866-91-8 CA
CN Urea, N-[2-(7-fluoro-2,3-dihydro-4H-1,4-benzoxazin-4-yl)ethyl]-N'-(1-methyl-5-isoquinolinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 15 CA COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 139:79144 CA
TITLE: Preparation of 5-member cyclic compounds as antiinflammatory agents
INVENTOR(S): Fujiwara, Norio; Fujita, Kazushi; Yasutoku, Fujio; Kanzawa, Toshihige; Kawakami, Hajime
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 72 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003192591	A2	20030709	JP 2001-396157	20011227

PRIORITY APPLN. INFO.: JP 2001-396157 20011227
OTHER SOURCE(S): MARPAT 139:79144
GI


I

AB The title compds. (I; X = O, S; R1 = H, (substituted)alkyl, etc.; R2 = (substituted)alkyl or aryl; Y1 = alkylene, etc.; R3 = (substituted)aryl; Y2 = (substituted)alkylene; r4 = H, alkanoyl, etc.; R5 = H, etc.) and their salts are claimed as antiinflammatory agents antiallergics by inhibiting leukocyte infiltration and are useful for treatment of autoimmune diseases. I and their salts were prepared

IT **553684-63-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 5-member cyclic compds. as antiinflammatory agents)

RN 553684-63-2 CA
CN Carbamic acid, [3-[[(5-isoquinolinylamino)thioxomethyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 15 CA COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 123:198626 CA
TITLE: Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
INVENTOR(S): Chang, George; Hamanaka, Ernest S.; Mccarthy, Peter A.; Truong, Thien; Walker, Frederick J.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 36 pp. Cont.-in-part of U.S. Ser. No. 648,677, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5362878	A	19941108	US 1992-916651	19920720
ES 2076865	B1	19960801	ES 1993-1508	19930705
ES 2076865	A1	19951101		
US 5656634	A	19970812	US 1994-251075	19940531

PRIORITY APPLN. INFO.: US 1991-648677 B2 19910321
US 1992-916651 19920720
OTHER SOURCE(S): MARPAT 123:198626
GI


I

AB Compds. of the formula I wherein R21 is C1-3-alkyl and R22 is H or C1-3-alkyl which are intermediates useful in the preparation of compds. of the formula R1NHCOQ (II) and the pharmaceutically acceptable salts thereof, wherein Q and R1 are as defined in the specification. The compds. of formula II are inhibitors of acyl CoA: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents (no data). Pharmaceutical formulations were given.

IT **134989-87-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(intermediates for making N-aryl and N-heteroarylamide and urea derivs. as inhibitors of acyl CoA: cholesterol acyl transferase)

RN 134989-87-0 CA
CN Urea, N-heptyl-N'-5-isoquinolinyl-N-[[4-(3-methylbutyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 15 CA COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 11 OF 15 CA COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 122:105879 CA
TITLE: Preparation of imidazo[1,2-a]pyridines as bradykinin antagonists.
INVENTOR(S): Oku, Teruo; Kayakiri, Hiroshi; Satoh, Shigeki; Abe, Yoshito; Yuki, Sawada; Tanaka, Hirokazu
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 117 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 596406	A1	19940511	EP 1993-117474	19931028
EP 596406	B1	19981216		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AU 9350242	A1	19940512	AU 1993-50242	19931026
AU 686115	B2	19980205		
ZA 9308011	A	19940609	ZA 1993-8011	19931027
IL 107426	A1	19970713	IL 1993-107426	19931027
AT 174596	E	19990115	AT 1993-117474	19931028
ES 2125294	T3	19990301	ES 1993-117474	19931028
CA 2102137	AA	19940503	CA 1993-2102137	19931101
CN 1089947	A	19940727	CN 1993-119684	19931101
HU 66302	A2	19941128	HU 1993-3119	19931102
JP 07300478	A2	19951114	JP 1993-274643	19931102
JP 2763036	B2	19980611		
US 5574042	A	19961112	US 1995-441786	19950516
US 5750699	A	19980512	US 1996-662198	19960612

PRIORITY APPLN. INFO.:

GB 1992-22947	A	19921102
GB 1993-4249	A	19930303
US 1993-142967	B2	19931029
US 1994-235632	B1	19940429
US 1995-441786	A3	19950516

OTHER SOURCE(S): MARPAT 122:105879
GI



I

AB Title compds. [I; R1 = halo; R2, R3 = H, alkyl, haloalkyl, acyl, R4 = aryl having suitable substituent(s), heterocyclyl optionally having suitable substituent(s); Q = O or NR11; R11 = H, acyl; and A = alkylene], were prepared Thus, 8-(2,6-dichloro-3-nitrobenzyloxy)-2-methylimidazo[1,2-a]pyridine was stirred with N-bromosuccinimide in EtOH/dioxane to give

L4 ANSWER 11 OF 15 CA COPYRIGHT 2005 ACS on STN (Continued)

3-bromo-8-(2,6-dichloro-3-nitrobenzyloxy)-2-methylimidazo[1,2-a]pyridine. I at 10-5 M gave 95-100% inhibition of 3H-bradykinin binding to guinea pig ileum prepns.

IT **160645-13-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as bradykinin antagonist)

RN 160645-13-6 CA

CN Acetamide, N-[3-[[(3-bromo-2-methylimidazo[1,2-a]pyridin-8-yl)oxy]methyl]-2,4-dichlorophenyl]-2-[[(5-isoquinolinylamino)carbonyl]amino]-N-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 15 CA COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 116:194114 CA
TITLE: Antiparasitic agents. Part XV. Synthesis of 2-substituted 1(3)H-imidazo[4,5-f]isoquinolines as anthelmintic agents
AUTHOR(S): Kumar, Pramod; Agarwal, Shiv K.; Bhakuni, D. S.
CORPORATE SOURCE: Div. Med. Chem., Cent. Drug Res. Inst., Lucknow, 226 001, India
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1992), 31B(3), 177-82
CODEN: IJSBDB; ISSN: 0376-4699
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I II

AB 5-(2,4-Dioxo-1H-quinazolin-3-yl)isoquinoline (I) and 2-(methyl-/carbomethoxyamino-/furyl-/trifluoromethyl)-1(3)H-imidazo[4,5-f]isoquinolines, e.g. II, were synthesized and tested for their anthelmintic and antifilarial activities against Ancylostoma ceylanicum, Nippostrongylus brasiliensis, Hymenolepis nana, and Litomosides carinii. Thus, 5-acetamidoisoquinoline was nitrated followed by reduction to give 5-acetamido-6-aminoisoquinoline, which was cyclized by HCl to give II.

IT **140192-80-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 140192-80-9 CA

CN Thiourea, N-ethyl-N'-5-isoquinolinyl- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 15 CA COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 115:71632 CA
TITLE: Preparation of new N-aryl and N-heteroaryl amide and -urea derivatives as inhibitors of acyl coenzyme A:cholesterol acyltransferase
INVENTOR(S): McCarthy, Peter A.; Walker, Frederick J.; Truong, Thien; Hamanaka, Ernest S.; Chang, George
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 85 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 418071	A2	19910320	EP 1990-310009	19900913
EP 418071	A3	19920325		
EP 418071	B1	19950426		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
WO 9104027	A1	19910404	WO 1989-US4033	19890915
W: FI, HU, NO, RO, SU, US				
IL 95610	A1	19941229	IL 1990-95610	19900907
DD 298092	A5	19920206	DD 1990-343971	19900912
CA 2025301	AA	19910316	CA 1990-2025301	19900913
CA 2025301	C	20011016		
EP 609960	A1	19940810	EP 1994-200437	19900913
EP 609960	B1	19990303		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 121730	E	19950515	AT 1990-310009	19900913
ES 2071033	T3	19950616	ES 1990-310009	19900913
AT 177082	E	19990315	AT 1994-200437	19900913
ES 2127878	T3	19990501	ES 1994-200437	19900913
NO 9004022	A	19910318	NO 1990-4022	19900914
CN 1050183	A	19910327	CN 1990-108294	19900914
HU 54625	A2	19910328	HU 1990-5991	19900914
AU 9062553	A1	19910418	AU 1990-62553	19900914
AU 652345	B2	19940825		
JP 03120243	A2	19910522	JP 1990-245969	19900914
JP 08025974	B4	19960313		
ZA 9007346	A	19920527	ZA 1990-7346	19900914
PL 165370	B1	19941230	PL 1990-286899	19900914
PL 165357	B1	19941230	PL 1990-291470	19900914
HU 70027	A2	19950928	HU 1993-2945	19900914
FI 111362	B1	20030715	FI 1990-4537	19900914
PRIORITY APPLN. INFO.:			WO 1989-US4033 A	19890915
			EP 1990-310009 A3	19900913

OTHER SOURCE(S): MARPAT 115:71632
GI

L4 ANSWER 13 OF 15 CA COPYRIGHT 2005 ACS on STN (Continued)



I

AB Approx. 250 title amides and ureas R1NHCOQ [Q = CR2R3R4, NR5R6; R1 = (substituted) pyridyl, pyrimidinyl, quinolinyl, pyridoimidazolyl, etc., substituted Ph; R2-R4 = H, alkyl, hydrocarbyl, XR7, phenylalkyl, cycloalkyl; or R3R3 forms cycloalkyl, cycloalkenyl, bicycloalkyl, etc.; R5, R6 = alkyl, phenylalkyl, alkylphenylalkyl; R7 = alkyl, cycloalkyl, phenylalkyl, thiazolyl, pyridyl, etc.; X = O, S, SO, SO2, NH, etc.; numerous provisos] were prepared as hypolipidemics and antiatherosclerotics (no data). For example, 2-(hexylthio)decanoic acid was refluxed with SOCl2 in C6H6 to give the acid chloride, which was added to 5-amino-4,6-bis(methylthio)-2-methylpyrimidine in CH2Cl2 followed by refluxing and purification to give 72.4% title amide I.
IT **134989-87-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as hypolipidemic)
RN 134989-87-0 CA
CN Urea, N-heptyl-N'-5-isoquinolinyl-N-[[4-(3-methylbutyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 15 CA COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 93:26292 CA
TITLE: Isoquinoline derivatives
PATENT ASSIGNEE(S): Rhone-Poulenc Industries S. A., Fr.
SOURCE: Belg., 33 pp.
CODEN: BEXXAL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 875797	A1	19791023	BE 1979-194791	19790423
FR 2424270	A1	19791123	FR 1978-12026	19780424
FR 2424270	B1	19800919		
FR 2449087	A2	19800912	FR 1979-4004	19790216
NL 7902993	A	19791026	NL 1979-2993	19790417
AU 7946219	A1	19791101	AU 1979-46219	19790420
GB 2020280	A	19791114	GB 1979-13821	19790420
GB 2020280	B2	19820728		
JP 55007260	A2	19800119	JP 1979-48895	19790420
ZA 7901893	A	19800430	ZA 1979-1893	19790420
DK 7901669	A	19791025	DK 1979-1669	19790423
SE 7903554	A	19791025	SE 1979-3554	19790423
ES 479878	A1	19800816	ES 1979-479878	19790424
ES 482070	A1	19800401	ES 1979-482070	19790629
PRIORITY APPLN. INFO.:			FR 1978-12026 A	19780424
			FR 1979-4004 A	19790216

GI



I II

AB The cyclocondensation reaction of aminoisoquinolines I [Z (in the 4-, 5-, 6-, 7-, or 8-position) = S-alkylisothioureido, NHCS2H alkyl ester, isothiocyanato; R and R1 (same or different) are H, halo, alkyl, alkoxy, alkoxyalkyl, alkylthio, dialkylamino] with H2NCH2CH2NHR2 (R2 = H, hydroxyalkyl) gave the resp. (imidazolinylamino)isoquinolines II, useful as antihypertensives (no data). 4-(Thioureido)isoquinoline was S-methylated, and the isothiourea derivative obtained was heated 7 h with H2NCH2CH2NH2 in EtOH to give 4-[(4,5-dihydro-2-imidazolyl)amino]isoquinoline.
IT **72677-81-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deacylation of)
RN 72677-81-7 CA
CN Benzamide, N-[(5-isoquinolinylamino)thioxomethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 15 CA COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 15 OF 15 CA COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 92:111013 CA
TITLE: Isoquinoline derivatives
INVENTOR(S): Deprez, Dominique; Farge, Daniel; Hucherot, Jean Jaques; Moutonnier, Claude
PATENT ASSIGNEE(S): Rhone-Poulenc Industries S. A., Fr.
SOURCE: Ger. Offen., 40 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2916577	A1	19791031	DE 1979-2916577	19790424
FR 2424270	A1	19791123	FR 1978-12026	19780424
FR 2424270	B1	19800919		
FR 2449087	A2	19800912	FR 1979-4004	19790216
NL 7902993	A	19791026	NL 1979-2993	19790417
AU 7946219	A1	19791101	AU 1979-46219	19790420
GB 2020280	A	19791114	GB 1979-13821	19790420
GB 2020280	B2	19820728		
JP 55007260	A2	19800119	JP 1979-48895	19790420
ZA 7901893	A	19800430	ZA 1979-1893	19790420
DK 7901669	A	19791025	DK 1979-1669	19790423
SE 7903554	A	19791025	SE 1979-3554	19790423
ES 479878	A1	19800816	ES 1979-479878	19790424
ES 482070	A1	19800401	ES 1979-482070	19790629

PRIORITY APPLN. INFO.: FR 1978-12026 A 19780424
FR 1979-4004 A 19790216

GI



I

AB The antihypertensive (no data) compds. I R = H, hydroxyalkyl; R1 and R2 = H, halogen, alkyl, alkoxy, alkoxyalkyl, alkylthio, dialkylamino) and their salts were prepared Thus, 5-(2-methylisothioureido)isoquinoline-HI reacted with H2NCH2CH2NH2 in EtOH to give 4-[(4,5-dihydro-2-imidazolyl)amino]isoquinoline.

IT **72677-81-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)

RN 72677-81-7 CA
CN Benzamide, N-[(5-isoquinolinylamino)thioxomethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 15 CA COPYRIGHT 2005 ACS on STN (Continued)



10/616,579

```
=> file uspatfull

=> s l3
L5            9 L3

=> d ibib abs 1-9
```

L5 ANSWER 1 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2004:268341 USPATFULL
TITLE: Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor
INVENTOR(S): Lee, Chih-Hung, Vernon Hills, IL, UNITED STATES
Bayburt, Erol K., Gurene, IL, UNITED STATES
DiDomenico, Stanley, JR., Richmond, IL, UNITED STATES
Drizin, Irene, Wadsworth, IL, UNITED STATES
Gomtsyan, Arthur R., Vernon Hills, IL, UNITED STATES
Koenig, John R., Chicago, IL, UNITED STATES
Perner, Richard J., Gurnee, IL, UNITED STATES
Schmidt, Robert G., JR., Waukegan, IL, UNITED STATES
Turner, Sean C., Evanston, IL, UNITED STATES
White, Tammie K., Gurnee, IL, UNITED STATES
Zheng, Guo Zhu, Lake Bluff, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004209884	A1	20041021
APPLICATION INFO.:	US 2004-842311	A1	20040510 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2003-364210, filed on 11 Feb 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-358220P	20020220 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEVEN F. WEINSTOCK, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
NUMBER OF CLAIMS: 84
EXEMPLARY CLAIM: 1
LINE COUNT: 7060
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I) ##STR1##

are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2004:203973 USPATFULL
TITLE: Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor
INVENTOR(S): Codd, Ellen, Blue Bell, PA, UNITED STATES
Dax, Scott L., Landenberg, PA, UNITED STATES
Jetter, Michele, UNITED STATES
McDonnell, Mark, Lansdale, PA, UNITED STATES
McNally, James J., Souderton, PA, UNITED STATES
Youngman, Mark, Warminster, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004157865	A1	20040812
APPLICATION INFO.:	US 2003-616579	A1	20030710 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-395728P	20020712 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
NUMBER OF CLAIMS: 120
EXEMPLARY CLAIM: 1
LINE COUNT: 7057
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to naphthol, quinoline and isoquinoline-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2004:203957 USPATFULL
TITLE: Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
INVENTOR(S): Lee, Chih-Hung, Vernon Hills, IL, UNITED STATES
Bayburt, Erol K., Gurnee, IL, UNITED STATES
DiDomenico, Stanley, JR., Richmond, IL, UNITED STATES
Drizin, Irene, Wadsworth, IL, UNITED STATES
Gomtsyan, Arthur R., Vernon Hills, IL, UNITED STATES
Koenig, John R., Chicago, IL, UNITED STATES
Perner, Richard J., Gurnee, IL, UNITED STATES
Schmidt, Robert G., JR., Waukegan, IL, UNITED STATES
Turner, Sean C., Evanston, IL, UNITED STATES
White, Tammie K., Gurnee, IL, UNITED STATES
Zheng, Guo Zhu, Lake Bluff, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004157849	A1	20040812
APPLICATION INFO.:	US 2003-634678	A1	20030805 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-364210, filed on 11 Feb 2003, PENDING		

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEVEN F. WEINSTOCK, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
NUMBER OF CLAIMS: 97
EXEMPLARY CLAIM: 1
LINE COUNT: 8346
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I) ##STR1##

are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:226385 USPATFULL
TITLE: Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
INVENTOR(S): Lee, Chih-Hung, Vernon Hills, IL, UNITED STATES
Bayburt, Erol K., Gurnee, IL, UNITED STATES
DiDomenico, Stanley, JR., Richmond, IL, UNITED STATES
Drizin, Irene, Wadsworth, IL, UNITED STATES
Gomtsyan, Arthur R., Vernon Hills, IL, UNITED STATES
Koenig, John R., Chicago, IL, UNITED STATES
Perner, Richard J., Gurnee, IL, UNITED STATES
Schmidt, Robert G., JR., Waukegan, IL, UNITED STATES
Turner, Sean C., Evanston, IL, UNITED STATES
White, Tammie K., Gurnee, IL, UNITED STATES
Zheng, Guo Zhu, Lake Bluff, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003158198	A1	20030821
APPLICATION INFO.:	US 2003-364210	A1	20030211 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-358220P	20020220 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEVEN F. WEINSTOCK, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
NUMBER OF CLAIMS: 84
EXEMPLARY CLAIM: 1
LINE COUNT: 7067
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compound of formula (I) ##STR1##

are novel VR1 antagonist that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:226375 USPATFULL
TITLE: Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
INVENTOR(S): Lee, Chih-Hung, Vernon Hills, IL, UNITED STATES
Bayburt, Erol K., Gurnee, IL, UNITED STATES
DiDomenico, Stanley, JR., Richmond, IL, UNITED STATES
Drizin, Irene, Wadsworth, IL, UNITED STATES
Gomtsyan, Arthur R., Vernon Hills, IL, UNITED STATES
Koenig, John R., Chicago, IL, UNITED STATES
Perner, Richard J., Gurnee, IL, UNITED STATES
Schmidt, Robert G., JR., Waukegan, IL, UNITED STATES
Turner, Sean C., Evanston, IL, UNITED STATES
White, Tammie K., Gurnee, IL, UNITED STATES
Zheng, Guo Zhu, Lake Bluff, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003158188	A1	20030821
APPLICATION INFO.:	US 2002-79324	A1	20020220 (10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEVEN F. WEINSTOCK, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
NUMBER OF CLAIMS: 68
EXEMPLARY CLAIM: 1
LINE COUNT: 3296
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 9 USPATFULL on STN
ACCESSION NUMBER: 1998:51772 USPATFULL
TITLE: Method of preparing certain 3-halo-imidazopyridines
INVENTOR(S): Oku, Teruo, Tsukuba, Japan
Kayakiri, Hiroshi, Tsukuba, Japan
Satoh, Shigeki, Tsukuba, Japan
Abe, Yoshito, Ibaraki, Japan
Sawada, Yuki, Tsukuba, Japan
Tanaka, Hirokazu, Takarazuka, Japan
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5750699		19980512
APPLICATION INFO.:	US 1996-662198		19960612 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-441786, filed on 16 May 1995, now patented, Pat. No. US 5574042 which is a continuation of Ser. No. US 1994-235632, filed on 29 Apr 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-142967, filed on 29 Oct 1993, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1992-22947	19921102
	GB 1993-4249	19930303

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dentz, Bernard
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
LINE COUNT: 7725
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to bradykinin antagonists of the formula: ##STR1## wherein R.sup.1 is halogen,

R.sup.2 and R.sup.3 are each hydrogen, lower alkyl, halo(lower)alkyl or acyl,

R.sup.4 is aryl having suitable substituent(s), or a heterocyclic group optionally having suitable substituent(s),

Q is O or N--R.sup.11, in which R.sup.11 is hydrogen or acyl, and

A is lower alkylene,

and pharmaceutically acceptable salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 9 USPATFULL on STN
ACCESSION NUMBER: 97:71069 USPATFULL
TITLE: N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
INVENTOR(S): Chang, George, Ivoryton, CT, United States
Hamanaka, Ernest S., Gales Ferry, CT, United States
McCarthy, Peter A., Pawcatuck, CT, United States
Truong, Thien V., Old Saybrook, CT, United States
Walker, Frederick J., Preston, CT, United States
PATENT ASSIGNEE(S): Pfizer Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5656634		19970812
APPLICATION INFO.:	US 1994-251075		19940531 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1992-916651, filed on 20 Jul 1992, now patented, Pat. No. US 5362878 which is a continuation-in-part of Ser. No. US 1991-648677, filed on 21 Mar 1991, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rotman, Alan L.
ASSISTANT EXAMINER: Mach, D. Margaret M.
LEGAL REPRESENTATIVE: Richardson, Peter C., Ginsburg, Paul H., Bekelnitzky, Seymour G.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 3701
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the formula ##STR1## the pharmaceutically acceptable salts thereof, wherein Q and R.sup.1 are as defined below, and novel carboxylic acid and acid halide intermediates used in the synthesis of such compounds. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 9 USPATFULL on STN
ACCESSION NUMBER: 96:104005 USPATFULL
TITLE: Imidazo [1,2-a] pyridines and their pharmaceutical use
INVENTOR(S): Oku, Teruo, Tsukuba, Japan
Kayakiri, Hiroshi, Tsukuba, Japan
Satoh, Shigeki, Tsukuba, Japan
Abe, Yoshito, Inashiki, Japan
Sawada, Yuki, Tsukuba, Japan
Tanaka, Hirokazu, Takarazuka, Japan
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd, Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5574042		19961112
APPLICATION INFO.:	US 1995-441786		19950516 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-235632, filed on 29 Apr 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-142967, filed on 29 Oct 1993, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1992-22947	19921102
	GB 1993-4249	19930303

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dentz, Bernard
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 7946
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to novel bradykinin antagonists of the formula: ##STR1## wherein R.sup.1 is halogen,

R.sup.2 and R.sup.3 are each hydrogen, lower alkyl, halo(lower)alkyl or acyl,

R.sup.4 is aryl having suitable substituent(s), or a heterocyclic group optionally having suitable substituent(s),

Q is O or N--R.sup.11, in which R.sup.11 is hydrogen or acyl, and

A is lower alkylene,

and pharmaceutically acceptable salts thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 9 USPATFULL on STN

ACCESSION NUMBER:	94:97714 USPATFULL
TITLE:	Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
INVENTOR(S):	Chang, George, Ivoryton, CT, United States Hamanaka, Ernest S., Gales Ferry, CT, United States McCarthy, Peter A., Pawcatuck, CT, United States Truong, Thien, Saybrook, CT, United States Walker, Frederick J., Preston, CT, United States
PATENT ASSIGNEE(S):	Pfizer Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5362878		19941108
APPLICATION INFO.:	US 1992-916651		19920720 (7)

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-648677, filed on 21 Mar 1991, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Chang, Celia
LEGAL REPRESENTATIVE:	Richardson, Peter C., Ginsburg, Paul H., Bekelnitzky, Seymour G.
NUMBER OF CLAIMS:	5
EXEMPLARY CLAIM:	1
LINE COUNT:	3480

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula ##STR1## wherein R.sup.21 and R.sup.22 are as defined in the specification which are intermediates useful in the preparation of compounds of the formula ##STR2## and the pharmaceutically acceptable salts thereof, wherein Q and R.sup.1 are as defined in the specification. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

10/616,579

```
=> d his

     (FILE 'HOME' ENTERED AT 14:41:04 ON 09 MAR 2005)

     FILE 'REGISTRY' ENTERED AT 14:41:08 ON 09 MAR 2005
L1               STRUCTURE UPLOADED
L2            20 S L1 SAM
L3           325 S L1 FULL

     FILE 'CA' ENTERED AT 14:41:29 ON 09 MAR 2005
L4            15 S L3

     FILE 'USPATFULL' ENTERED AT 14:41:53 ON 09 MAR 2005
L5             9 S L3

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

STN INTERNATIONAL LOGOFF AT 14:42:25 ON 09 MAR 2005
```